Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Christy J. Wilson
Sr. Director, Pharma and Biotech Segment
Connect with Christy J. Wilson on LinkedIn
Follow Christy J. Wilson on Twitter
About the author:
Christy brings more than 20 years of global life science and healthcare industry experience to her role as Senior Director, Segment Marketing for the biopharmaceutical industry segment at Elsevier. In this capacity she is focused on understanding biopharmaceutical R&D challenges and the implications for Elsevier in terms of market led growth opportunities that will improve productivity and success for industry executives and their teams. She also plays a key role in increasing Elsevier’s share-of-voice and market share through strategic go-to-market planning and execution.
Prior to joining Elsevier, Christy held senior marketing and business development roles in Wolters Kluwer’s Pharma Solutions Business Unit where she was responsible for product management and marketing of the Adis portfolio of drug focused journals and newsletters, pipeline and clinical trials intelligence tools, and pharmacovigilance solutions. During her Wolters Kluwer tenure, Christy also worked in the group’s Healthcare Analytics business, a business that provided powerful data, applications, analytics, and consulting to help companies gain deep insight into the pharmaceutical market.
Christy resides in the greater New York City area and holds an MBA in International Business from DePaul University (Chicago) and a BS in Marketing, from Miami University (Ohio).
Posts by Christy J. Wilson
Posted on June 21st, 2016 in Pharma R&D
Biomarker-based patient selection for clinical trials, a hallmark of precision medicine, is gaining traction. On Monday June 6, a team of researchers reported at the American Society of Clinical Oncology annual meeting and in an online paper in JAMA Oncology that biomarker selection results in better outcomes in Phase l trials. (more…)
Posted on June 20th, 2016 in Pharmacovigilance
The scope of pharmacovigilance has expanded. Regulatory agencies have placed new demands on how pharmaceutical companies are expected to ensure the safety of their products and manage benefit–risk. (more…)
Posted on June 15th, 2016 in Pharma R&D
In silico modeling is arguably one of the hottest trends in life sciences R&D today. We know that bringing drug discovery to the desktop impacts cost. (more…)
Posted on May 4th, 2016 in Pharma R&D
Fifty-four percent. That’s the percentage of “all active drugs” sourced via open innovation models for the 12 largest biopharma company pipelines in 2014. (more…)